Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives $1.35 Average PT from Brokerages

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP - Get Free Report) have received a consensus recommendation of "Hold" from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $1.35.

Several equities research analysts recently weighed in on ADAP shares. Wall Street Zen started coverage on Adaptimmune Therapeutics in a report on Friday, May 16th. They set a "buy" rating for the company. Scotiabank dropped their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Barclays cut their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating on the stock in a report on Wednesday, May 14th. HC Wainwright lowered their price target on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Guggenheim cut their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a report on Wednesday, March 26th.

Adaptimmune Therapeutics Trading Down 2.2%

Shares of ADAP stock traded down $0.01 on Friday, hitting $0.24. 557,296 shares of the company's stock traded hands, compared to its average volume of 1,674,224. The stock has a market capitalization of $63.53 million, a price-to-earnings ratio of -0.89 and a beta of 2.24. The company's fifty day simple moving average is $0.27 and its 200 day simple moving average is $0.41. Adaptimmune Therapeutics has a one year low of $0.20 and a one year high of $1.48. The company has a debt-to-equity ratio of 4.24, a quick ratio of 1.79 and a current ratio of 2.02.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). The business had revenue of $7.29 million during the quarter, compared to analyst estimates of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. Equities analysts forecast that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Trading of Adaptimmune Therapeutics

Several large investors have recently added to or reduced their stakes in ADAP. Long Focus Capital Management LLC boosted its stake in shares of Adaptimmune Therapeutics by 15.9% during the 1st quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company's stock valued at $4,680,000 after purchasing an additional 3,262,294 shares in the last quarter. Two Seas Capital LP boosted its position in Adaptimmune Therapeutics by 38.4% during the 1st quarter. Two Seas Capital LP now owns 20,529,685 shares of the biotechnology company's stock valued at $4,044,000 after acquiring an additional 5,694,539 shares in the last quarter. Renaissance Technologies LLC boosted its position in Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock valued at $1,361,000 after acquiring an additional 869,949 shares in the last quarter. Rock Springs Capital Management LP lifted its stake in shares of Adaptimmune Therapeutics by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after purchasing an additional 58,000 shares during the period. Finally, Acadian Asset Management LLC boosted its position in shares of Adaptimmune Therapeutics by 334.8% during the first quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company's stock valued at $424,000 after purchasing an additional 1,707,999 shares in the last quarter. Institutional investors own 31.37% of the company's stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.